Replicating herpes simplex virus vectors for cancer gene therapy

Bibliography

• TJUVAJEV JG, CHEN SH, JOSHI A et al Imaging adenoviral-mediated herpes virus thymidine gene transfer and expression in vivo. Cancer Res (1999) 59(20):5186–5193.
   PubMed Web of Science ®Google Scholar
• RAM Z, CULVER KW, WALBRIDGE S, BLAESE RM,OLDFIELD EH: In situ retroviral-mediated gene transfer for the treatment of brain tumors. Cancer Res. (1993) 53(1):83–88.
   PubMedGoogle Scholar
• TOURAINE RL, ISHII-MORITA H, RAMSEY WJ, BLAESE RM:The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther. (1998) 5(12):1705–1711.
   PubMed Web of Science ®Google Scholar
• BLAESE RM: Gene therapy for cancer. Sci. Am. (1997)276(6):111–115.
   PubMed Web of Science ®Google Scholar
• WILDNER 0, MORRIS JC, VAHANIAN NN et al.: Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV. Gene Ther. (1999) 6(1):57–62.
   Google Scholar
• BLAESE RM, ISHII-MORITA H, MULLEN C et al.: In situ delivery of suicide genes for cancer treatment. Eur. J. Cancer (1994) 30A(8):1190–1193.
   PubMed Web of Science ®Google Scholar
• CULVER KW: Gene therapy for malignant neoplasms of the CNS [review]. Bone Marrow Transplant. (1996) 18\(Suppl. 3):S6–9.
   Google Scholar
• OLDFIELD EH, RAM Z, CULVER KW et al.: Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Human Gene Ther. (1993) 4(1)39–69.
   Google Scholar
• KRUMMENACHER C, RUX AH, WHITBECK JC et al.: Thefirst immunoglobulin-like domain of HveC is sufficient to bind herpes simplex virus gD with full affinity, while the third domain is involved in oligomerization of HveC. J. Virol. (1 9 9 9) 73(10):8127–8137.
   Google Scholar
• DAMIENS E, EL YAZIDI I, MAZURIER J et al: Role ofheparan sulphate proteoglycans in the regulation of human lactoferrin binding and activity in the MDA-MB-231 breast cancer cell line. Eur. J Cell Biol (1998) 77(4):344–351.
   PubMed Web of Science ®Google Scholar
• LAMBRECHT V, LE BOURHIS X, TOILLON RA, BOILLY BHONDERMARCK H: Alterations in both heparan sulfate proteoglycans and mitogenic activity of fibroblast growth factor-2 are triggered by inhibitors of proliferation in normal and breast cancer epithelial cells. Exp. Cell Res. (1998) 245(2)239–244.
   Google Scholar
• KLEEFF J, ISHIWATA T, KUMBASAR A et al.: The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J. Clin. Invest. (1998) 102(9): 1662–1673.
   PubMed Web of Science ®Google Scholar
• PARTHASARATHY N, GOTOW LF, BOTTOMS JD et al.:Oligosaccharide sequence of human breast cancer cell heparan sulfate with high affinity for laminin. J. Biol. Chem. (1998) 273(33):21111–21114.
   PubMed Web of Science ®Google Scholar
• JAYSON GC, LYON M, PARASKEVA C et al.: Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J. Biol. Chem. (1998) 273(1):51–57.
   PubMed Web of Science ®Google Scholar
• JACOBS AL, JULIAN J, SAHIN AACARSON DD: Heparin/heparan sulfate interacting protein expres-sion and functions in human breast cancer cells and normal breast epithelia. Cancer Res. (1 9 9 7) 57(22):5148–5154.
   Google Scholar
• NACKAERTS K, VERBEKEN E, DENEFFE G et al.: Heparan sulfate proteoglycan expression in human lung-cancer cells. Int. J. Cancer (1997) 74(3):335–345.
   PubMed Web of Science ®Google Scholar
• SARAL R: Oral complications of cancer therapies. Management of acute viral infections. NCI Monographs (1990) 9:107–110.
   PubMedGoogle Scholar
• EPSTEIN JB: Infection prevention in bone marrow transplantation and radiation patients. NCI Monographs (1990) 9:73–85.
   Google Scholar
• KENNEDY PG: Herpes simplex virus and the nervous system [review] [70 refs]. Postgrad. Med. J. (1984) 60(702):253–259.
   PubMed Web of Science ®Google Scholar
• HE B, GROSS M, ROIZMAN B The y34.5 protein of herpes simplex virus 1 has the structural and functional attributes of a protein phosphatase 1 regulatory subunit and is present in a high molecular weight complex with the enzyme in infected cells. J. Biol. Chem. (1998) 273(33):20737–20743.
   Google Scholar
• •An important paper describing the function of the HSV y34.5 protein in the cell.
   Google Scholar
• CHOU J, KERN ER, WHITLEY RJ, ROIZMAN B: Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science (1990) 250(4985):1262–1266.
   Google Scholar
• •The first report of a neurovirulence function in the HSV genome.
   Google Scholar
• YAZAKI T, MANZ HJ, RABKIN SD, MARTUZA RL: Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. (1995) 55(20:4752–4756.
   PubMedGoogle Scholar
• HUNTER WD, MARTUZA RL, FEIGENBAUM F et al.: Attenuated, replication-competent herpes simplex virus Type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates./ Virol. (1999) 73(8):6319–6326.
   Google Scholar
• MINETA T, RABKIN SD, YAZAKI T, HUNTER WD, MARTUZA RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. (1995) 1(9):938–943.
   PubMed Web of Science ®Google Scholar
• •An important early paper describing the properties of G207.
   Google Scholar
• TODA M, RABKIN SD, MARTUZA RL: Treatment of human breast cancer in a brain metastatic model by G207, a replication competent multimutated herpes simplex virus 1. Human Gene Ther. (1998) 9(15):2177–2185.
   PubMed Web of Science ®Google Scholar
• TODO T, RABKIN SD, SUNDERESAN P et al.: Systemicantitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum. Gen. Ther. (1999) 10(17):2741–2755.
   PubMed Web of Science ®Google Scholar
• TODA M, MARTUZA RL, KOJIMA H, RABKIN SD: In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J. Immunol. (1998) 160(9):4457–4464.
   PubMed Web of Science ®Google Scholar
• TODA M, RABKIN SD, KOJIMA H, MARTUZA RL: Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Human Gene Ther. (1999) 10(3):385–393.
   PubMed Web of Science ®Google Scholar
• •The first report to study the effect of G207 in a brain tumour model of immunocompetent animals.
   Google Scholar
• CHAHLAVI A, RABKIN SD, TODO T, SUNDERESAN P, MARTUZA RL: Effect of prior exposure to herpes simplex virus 1 on viral vector mediated tumor therapy in irnmunocompetent mice. Gene. Ther. (1999) 6:1751–1758.
   PubMed Web of Science ®Google Scholar
• TODO T, RABKIN SD, CHAHLAVI A, MARTUZA RL: Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum. Gene. Ther. (1999) 10(17):2869–2878.
   PubMed Web of Science ®Google Scholar
• MACLEAN AR, UL-FAREED M, ROBERTSON L, HARLAND J,BROWN: Herpes simplex virus Type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J. Gen. Virol. (1991) 72(Pt 3):631–639.
   PubMed Web of Science ®Google Scholar
• LASNER TM, TAL-SINGER R, KESARI S et al.: Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice. J Neurovirol. (1998) 4(1):100–105.
   Google Scholar
• MCMENAMIN MM, BYRNES AP, CHARLTON HM et al.: A y34.5 mutant of herpes simplex 1 causes severe inflam-mation in the brain. Neuroscience (1998) 83:1225–1237.
   Google Scholar
• VALYI-NAGY T, FAREED MUO'KEEFE JS: The herpes simplex virus Type 1 strain 17+ gamma 34.5 deletion mutant 1716. J. Gen. Virol. (1994) 75\(Pt 8):2059–2063.
   Google Scholar
• KUCHARCZUK JC, RANDAZZO B, CHANG MY, AMIN KMELSHAMI: Use of a replication-restricted' herpes virus to treat experimental human malignant mesothelioma. Cancer Res. (1997) 57(3):466–471.
   PubMed Web of Science ®Google Scholar
• KOOBY DA, CAREW JF, HALTERMAN MW et al.: Oncolyticviral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J. (1999) 13(10:1325–1334.
   PubMed Web of Science ®Google Scholar
• •An important paper showing the antitumor efficacy of G207 delivered regionally for the treatment of colorectal metastases in the liver.
   Google Scholar
• WALKER JR, MCGEAGH KG, SUNDARESAN P et al.: Local and systemic therapy of human prostate adenocarci-noma with the conditionally replicating herpes simplex virus vector G207. Human Gene Ther. (1999) 10(13):2237–2243.
   PubMed Web of Science ®Google Scholar
• •A paper showing the effectiveness of HSV delivered systemically for the treatment of experimental prostate cancer.
   Google Scholar
• ADVANI SJ, CHUNG SM, YAN SY et al.: Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res. (1999) 59(9):2055–2058.
   PubMed Web of Science ®Google Scholar
• •An important paper showing that attenuated HSV is capable of killing radiation-resistant cancer cells.
   Google Scholar
• ADVANI SJ, CHMURA SJWEICHSELBAUM RR: Radioge-netic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumors. Semin. Oncol. (1997) 24(6):633–638.
   PubMed Web of Science ®Google Scholar
• WEICHSELBAUM RR, HALLAHAN D, FUKS ZKUFE D: Radiation induction of immediate early genes: effectors of the radiation-stress response. Int.J. Radiat. Oncol. Biol. Phys. (1994) 30(1):229–234.
   PubMed Web of Science ®Google Scholar
• ADVANI SJ, SIBLEY GS, SONG PY et al.: Enhancement ofreplication of genetically engineered herpes simplex viruses. Gene Ther. (1998) 5(2):160–165.
   PubMed Web of Science ®Google Scholar
• CHAHLAVI A, TODO T, MARTUZA RL, RABKIN SD: Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia (1999) 1:162–169.
   PubMedGoogle Scholar
• ANDREANSKY S, HE B, VAN coil' J et al Treatment of intracranial g,liomas in irnmunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. (1998) 5(1):121–130. Exp. Opin. Pharmacother. (2000) 1(4) © Ashley Publications Ltd. All rights reserved.
   Google Scholar
• PARKER JN, GILLESPIE GY, LOVE CE et al.: Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Natl. Acad. Sci. USA (2000) 97:2208-2213 Sonia N Yeungl & Frank Tufaro1,2t
   Google Scholar